PharmaResearch: Strong Profit Growth and High Margins Alongside a 45.2% One-Year Share Price Decline

Thesis

The data supports a picture of a fast-growing, highly profitable company: revenue rose 53.2% in 2025 and trailing net income reached ₩185.7B. Return on equity of 28.7% and a near debt-free balance sheet add to that. At the same time, the share price has fallen 13.2% in one month, 10.1% in three months and 45.2% in one year, while earnings kept rising. The data does not explain the gap between earnings and price. No news headlines, investor flow data, foreign ownership or short balance figures are available, so the cause of the decline cannot be identified from this data.

Business overview

PharmaResearch (code 214450) is a Biotech & Pharma company listed on KOSDAQ since 2015-07-24, founded in 2001, with CEO 손지훈. It has 10,509,600 listed shares and a market capitalization of about ₩3.1T. Revenue has grown every year in the data, from ₩154.1B in 2021 to ₩194.8B in 2022, ₩261.0B in 2023, ₩350.1B in 2024 and ₩536.3B in 2025. The data does not describe products or business segments.

Financial analysis

All figures come from filed financial statements (DART). For the trailing twelve months to H1 2026, revenue was ₩603.6B, operating income ₩237.5B and net income ₩185.7B, giving an operating margin of 39.4% and a net margin of 30.8%. Annual operating margin rose from 34.1% in 2021 to 40.0% in 2025. Revenue growth was 26.4% in 2022, 34.0% in 2023, 34.1% in 2024 and 53.2% in 2025. Net income grew from ₩40.6B in 2022 to ₩165.1B in 2025. ROE was 26.9% in 2025 and 28.7% on a trailing basis. Liabilities to equity is 40.3%, cash is ₩220.3B against borrowings of only ₩423.7M, and trailing free cash flow is ₩137.9B.

Valuation

The current P/E is 16.8, P/B is 4.1 and P/S is 5.2, with a dividend yield of 1.4% and enterprise value of about ₩2.9T. At the end of 2025 the P/E was 25.7 and P/B was 6.1, so both multiples are lower now. Earlier year-end multiples are not available. Among the listed peers, P/E ratios are 43.1 for Samsung Biologics, 25.5 for Celltrion, 64.1 for Alteogen and 28.0 for Hanmi Pharm; HLB has no P/E. P/B ranges from 2.2 (Celltrion) to 23.1 (Alteogen), with Hanmi Pharm at 4.3. PharmaResearch's P/E is below all four peers with a figure. EV/EBITDA is not available.

Catalysts

• The half-year report for June 2026 was filed on 2026-08-14, following preliminary consolidated earnings on 2026-08-07, so the latest results are already public.
• A 5%+ holding report was filed on 2026-10-02, which indicates a change in a significant shareholder position, though details are not in the data.
• The company has held several investor relations events recently (2026-05-06, 06-09, 06-26, 08-06 and 09-01), showing regular communication with investors.
• The next earnings cycle is visible through the pattern of filings, with preliminary results and quarterly reports appearing each quarter, though specific dates are not given.

Risks

• The share price is down 45.2% over one year and has fallen 13.2% in the past month, showing strong negative momentum.
• The data offers no investor flow, foreign ownership or short balance information, so market positioning cannot be assessed.
• No news headlines are available, so the reason for the price decline is unknown.
• Revenue growth of 53.2% in 2025 was much higher than earlier years, and the data cannot show whether that pace is sustainable.
• The business depends on very high margins of about 40%, so any margin pressure would affect profit significantly.

Closing view

The filed financials show rapid growth, margins near 40%, strong returns and almost no debt, and the valuation multiples have fallen from year-end 2025 levels and sit below the peers shown. Against that, the share price has dropped sharply and the data cannot explain why, and key market indicators are missing. The evidence shows strong reported fundamentals alongside weak price performance, without clarifying what the market is concerned about.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationPharmaResearch: Strong Profit Growth and High Margins Alongside a 45.2% One-Year Share Price Decline